Voydeya™ (danicopan) – New orphan drug approval
April 1, 2024 - AstraZeneca announced the FDA approval of Voydeya (danicopan), as add-on therapy to Ultomiris® (ravulizumab) or Soliris® (eculizumab) for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).